NXTC vs. OCUP, HCWB, NBRV, AADI, GANX, EYEN, CASI, VYNE, IMRX, and UNCY Should you be buying NextCure stock or one of its competitors? The main competitors of NextCure include Ocuphire Pharma (OCUP), HCW Biologics (HCWB), Nabriva Therapeutics (NBRV), Aadi Bioscience (AADI), Gain Therapeutics (GANX), Eyenovia (EYEN), CASI Pharmaceuticals (CASI), VYNE Therapeutics (VYNE), Immuneering (IMRX), and Unicycive Therapeutics (UNCY). These companies are all part of the "pharmaceutical preparations" industry.
NextCure (NASDAQ:NXTC ) and Ocuphire Pharma (NASDAQ:OCUP ) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.
Ocuphire Pharma has higher revenue and earnings than NextCure. Ocuphire Pharma is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.
NextCure has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Comparatively, Ocuphire Pharma has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500.
In the previous week, Ocuphire Pharma had 15 more articles in the media than NextCure. MarketBeat recorded 15 mentions for Ocuphire Pharma and 0 mentions for NextCure. NextCure's average media sentiment score of 0.00 beat Ocuphire Pharma's score of -0.31 indicating that NextCure is being referred to more favorably in the media.
NextCure presently has a consensus target price of $6.00, indicating a potential upside of 259.28%. Ocuphire Pharma has a consensus target price of $18.75, indicating a potential upside of 1,012.76%. Given Ocuphire Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Ocuphire Pharma is more favorable than NextCure.
NextCure has a net margin of 0.00% compared to Ocuphire Pharma's net margin of -59.44%. Ocuphire Pharma's return on equity of -24.57% beat NextCure's return on equity.
NextCure received 43 more outperform votes than Ocuphire Pharma when rated by MarketBeat users. However, 68.00% of users gave Ocuphire Pharma an outperform vote while only 63.64% of users gave NextCure an outperform vote.
42.7% of NextCure shares are held by institutional investors. Comparatively, 15.0% of Ocuphire Pharma shares are held by institutional investors. 11.9% of NextCure shares are held by company insiders. Comparatively, 8.7% of Ocuphire Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary Ocuphire Pharma beats NextCure on 11 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding NXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
NextCure Competitors List
Related Companies and Tools
